Safety and Efficacy Study of High Dose Melphalan to Treat Multiple Myeloma

Inclusion Criteria: * Patients with greater or equal to 18 years, with a upper age limit of 65 years are eligible. * Multiple myeloma patients, symptoms conform to diagnosis of multiple myeloma of IMWG2003/WHO2008 criteria. * Patients with responsive disease after induction therapy not more than 6 courses of treatment * A complete response * A very good partial response * A partial response * At least 4 weeks long from last cytotoxic treatment(exclude Bortezomib, thalidomide, dexamethasone); * Eastern Cooperative Oncology Group (ECOG) scored 0 or 1 Patient has an absolute neutrophil count of ≥1.5×109/L and platelet count≥80×109/L; * Calculated creatinine clearance \>50ml/min by Cockcroft-Gault formula or collect urine within 24 hours. * Patient with a total bilirubin ≤1.5 times of normal upper limit, AST,ALT≤2.5times of normal upper limit; * Cardio-pulmonary function is adequate to conduct autologous stem cell transplant. * Ratio of body weight and ideal body weight \<175%; * All patients should have a life expectancy of more than 12 weeks * Signed informed consent form voluntarily Exclusion Criteria: * CD34 positive hematopoietic stem cell collected \<2.0×106/kg * Patients have a psychiatric history * Female subject is pregnant or breast-feeding * Patients are hypersensitive to this trial product or other alkylating agents * Participate of other clinical trials within the past 4 weeks Active CNS lesions * Concomitant of active infection or positive of HIV antibody * Concomitant of other un-healed malignancy * Left ventricular ejection fraction≤50% * Patients with serious thrombosis * Any severe concomitant disease that will expose study subjects to unacceptable risks. * Patients not suitable to enroll by investigators considerations.